[go: up one dir, main page]

PE20000281A1 - B-CELL INHIBITORS - Google Patents

B-CELL INHIBITORS

Info

Publication number
PE20000281A1
PE20000281A1 PE1999000110A PE00011099A PE20000281A1 PE 20000281 A1 PE20000281 A1 PE 20000281A1 PE 1999000110 A PE1999000110 A PE 1999000110A PE 00011099 A PE00011099 A PE 00011099A PE 20000281 A1 PE20000281 A1 PE 20000281A1
Authority
PE
Peru
Prior art keywords
halogen
alkyl
alcoxy
group
ilica
Prior art date
Application number
PE1999000110A
Other languages
Spanish (es)
Inventor
Rainer Albert
Christoph Heusser
Elsebeth Andersen
Alexander Hagenbach
Anette Wienand
Christos Papageorgiou
Max H Schreier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802842.6A external-priority patent/GB9802842D0/en
Priority claimed from GBGB9810688.3A external-priority patent/GB9810688D0/en
Priority claimed from GBGB9826553.1A external-priority patent/GB9826553D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20000281A1 publication Critical patent/PE20000281A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A AMIDAS DE FORMULA T-C(=Z)-NH-(CH2)n-W, DONDE 1) Z ES O; n ES 0; T ES UN GRUPO a; R6 ES H, ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR HALOGENO, OH, NR7R8, COOH, ENTRE OTROS; R7 Y R8 SON H, ALQUILO C1-C4, CHO, HETEROCICLO, ENTRE OTROS; R9 Y R10 SON ALQUILO C1-C6 SUSTITUIDO POR OH, NR7R8; W ES UN GRUPO b; X ES -CR1=, R1 ES H, F, CF3, ALQUILO C1-C4, NH2; R2 ES H, F, OH, ALCOXI C1-C4, CN, NO2, CF3, NHCO-ALQUILO C1-C4; R3 ES H, HALOGENO, CN, NO2, CF3, NH2, OH; R4 ES H, HALOGENO, CF3, ALCOXI C1-C4; R5 ES H, HALOGENO, ALCOXI C1-C4, TIOALQUILO C1-C4, CF3, NH2, ENTRE OTROS. 2)Z ES O o S; n ES 0 o 1; T ES UN GRUPO c; R11 ES H, CH3, C2H5; R12 ES H, HALOGENO, CICLOALQUILO C3-C6; R13 ES H, HALOGENO, OH, ALCOXI C1-C2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS AMIDA (4-CLORO-3-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, AMIDA (5-TRIFLUOROMETIL-PIRIDIN-2-ILICA) DE ACIDO QUINOLIN-8-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO INHIBE LA PRODUCCION DE ANTICUERPOS IgM DE CELULAS B; SIN BLOQUEAR LA ACTIVIDAD DE DIHIDRO-OROTATO DESHIDROGENASA (DHODH) Y SON UTILES PARA PREVENIR O REDUCIR LAS RESPUESTAS INMUNES DE ANTICUERPOSREFERS TO AMIDES OF FORMULA T-C (= Z) -NH- (CH2) n-W, WHERE 1) Z IS O; n IS 0; T IS A GROUP a; R6 IS H, C1-C6 ALKYL OPTIONALLY SUBSTITUTED BY HALOGEN, OH, NR7R8, COOH, AMONG OTHERS; R7 AND R8 ARE H, C1-C4 ALKYL, CHO, HETEROCYCLE, AMONG OTHERS; R9 AND R10 ARE C1-C6 ALKYL SUBSTITUTED BY OH, NR7R8; W IS A GROUP b; X IS -CR1 =, R1 IS H, F, CF3, C1-C4 ALKYL, NH2; R2 IS H, F, OH, C1-C4 ALCOXY, CN, NO2, CF3, NHCO-C1-C4 ALKYL; R3 IS H, HALOGEN, CN, NO2, CF3, NH2, OH; R4 IS H, HALOGEN, CF3, C1-C4 ALCOXY; R5 IS H, HALOGEN, C1-C4 ALCOXY, C1-C4 THIOALKYL, CF3, NH2, AMONG OTHERS. 2) Z IS O or S; n IS 0 or 1; T IS A GROUP c; R11 IS H, CH3, C2H5; R12 IS H, HALOGEN, C3-C6 CYCLOALKYL; R13 IS H, HALOGEN, OH, C1-C2 ALCOXY, AMONG OTHERS. PREFERRED COMPOUNDS AMIDE (4-CHLORO-3-TRIFLUOROMETHYL-PYRIDIN-2-ILICA) OF QUINOLIN-8-CARBOXYL ACID, AMIDE (5-TRIFLUOROMETIL-PIRIDIN-2-ILICA) OF QUINOLIN-8-CARBOXYL ACID, ENTRY. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. THE COMPOUND INHIBITS THE PRODUCTION OF B-CELL IgM ANTIBODIES; WITHOUT BLOCKING THE ACTIVITY OF DIHYDRO-OROTATE DEHYDROGENASE (DHODH) AND ARE USEFUL TO PREVENT OR REDUCE IMMUNE ANTIBODY RESPONSES

PE1999000110A 1998-02-10 1999-02-09 B-CELL INHIBITORS PE20000281A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802842.6A GB9802842D0 (en) 1998-02-10 1998-02-10 Organic compounds
GBGB9810688.3A GB9810688D0 (en) 1998-05-19 1998-05-19 Organic compounds
GBGB9826553.1A GB9826553D0 (en) 1998-12-02 1998-12-02 Organic compounds

Publications (1)

Publication Number Publication Date
PE20000281A1 true PE20000281A1 (en) 2000-05-15

Family

ID=27269204

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000110A PE20000281A1 (en) 1998-02-10 1999-02-09 B-CELL INHIBITORS

Country Status (5)

Country Link
AR (1) AR015514A1 (en)
AU (1) AU2832399A (en)
CO (1) CO4980854A1 (en)
PE (1) PE20000281A1 (en)
WO (1) WO1999041239A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012189A1 (en) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
NZ526336A (en) 2000-12-07 2004-11-26 Cv Therapeutics Inc Substituted 1, 3,5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7375232B2 (en) 2001-08-15 2008-05-20 E.I. Du Pont De Nemours And Company Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN102985405B (en) * 2010-07-02 2016-07-06 Aska制药株式会社 Heterocyclic compounds and p27Kip1 breakdown inhibitors
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHODS OF TREATING A MELANOMA
US9499484B2 (en) * 2012-04-02 2016-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Indole, indoline derivatives, compositions comprising them and uses thereof
AP2016009156A0 (en) 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PL3200786T3 (en) 2014-10-03 2020-03-31 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
US10730839B2 (en) * 2016-11-27 2020-08-04 Russell Dahl Quinolines as cytoprotective agents
CN111164075A (en) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 Fused Ring Derivatives as FGFR4 Inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1305458A (en) * 1969-02-26 1973-01-31
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
FR2121394A1 (en) * 1971-01-08 1972-08-25 Anvar 2-methyl indole 3-carboxylic acid amides - antiinflammatories analgesics, tranquillisers, fungicides, herbicides and inters
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands

Also Published As

Publication number Publication date
AR015514A1 (en) 2001-05-02
WO1999041239A1 (en) 1999-08-19
CO4980854A1 (en) 2000-11-27
AU2832399A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
PE20000281A1 (en) B-CELL INHIBITORS
AR016307A1 (en) IMIDAZOPIRIMIDINAS AND IMIDAZOPIRIDINAS, METHOD FOR THE TREATMENT OF NEUROLOGICAL AFFECTIONS, AND PHARMACEUTICAL COMPOSITION.
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
NO981496L (en) Imidazole derivatives with affinity for <alfa> 2 receptor activity
PE20051039A1 (en) [1,8] NAPHTHYRIDIN-2-ONAS AND RELATED COMPOUNDS
DE3855144D1 (en) Use of certain 5-HT3 receptor antagonists for the treatment of intestinal pain
PE46899A1 (en) N-PHENYL-SULFONAMIDE DERIVATIVES
PE20000564A1 (en) NEUROPEPTIDE Y5 RECEPTOR ANTAGONISTS
AR038883A1 (en) COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND A METHOD TO PREPARE THEM
ATE186727T1 (en) SUBSTITUTED 3-ARYLIDINENE-7-AZAOXINDOLE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
AR035695A1 (en) METALOPROTEINASE INHIBITING COMPOUNDS, PHARMACEUTICAL COMPOSITION, TREATMENT METHOD, AND USE OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
PE20000325A1 (en) DERIVATIVES OF 2-ARILETIL- (PIPERIDIN-4-ILMETIL) AMINE
MX174596B (en) PROCEDURE FOR THE PREPARATION OF ENOL-ETER DERIVATIVES OF OXICAMS
AR004015A1 (en) PROCEDURE FOR PREPARING QUINOLINE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND INTERMEDIARY COMPOUNDS
PT96070A (en) PROCESS FOR THE PREPARATION OF HETEROCYCLIC DERIVATIVES ACILO AMINODIOL BETA AMINO ACIDO
DK0812838T3 (en) Pyridonecarboxylic acid derivatives substituted with bicyclic amino group, esters and salts thereof, and bicyclic amine as intermediate
DE69316392D1 (en) AZANORADAMANTANE
GB2001309A (en) alpha -Halomethyl beta -(3-indolyl) amino acids and derivatives
ES8602712A1 (en) A PROCEDURE FOR PREPARING A RHODANINE DERIVATIVE
ATE188695T1 (en) INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE-1 INHIBITORS
EA200200682A1 (en) NEW COMPOUNDS OF N-BENZYLPIPERASINE, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HU0001727D0 (en) Novel 1-aza-2-alkyl-6-aryl-cycloalkane compounds, process for producing them and medicaments containing the same
PT911336E (en) PYRIDONACARBOXYLIC ACID DERIVATIVES AND INTERMEDIARIES FOR THEIR SYNTHESIS
PE20001035A1 (en) DERIVATIVES OF BENZOXAZINE AND BENZOTHIAZINE AS INHIBITORS OF NITROGEN MONOXIDE SYNTHASE
ES8201539A1 (en) Orthoarylideneaminophenethylamines and pharmaceutical compositions

Legal Events

Date Code Title Description
FC Refusal